CD274 and neoplasm: We used the data from a different type of tumor (IMvigor210CoreBiologies cohort on locally advanced or metastatic urothelial bladder cancer) to evaluate the ability of the DRGS score to predict PD-L1 blockade-based immunotherapy response, because of a lack of such a dataset in gastric cancer.